Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Groprinosin for recurrent airway inflammation in children with impaired cellular immunity
2013-003303-18Phase 4Terminated
- Sponsor
- Gedeon Richter Plc
- Start
- Jan 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, single-arm trial of inosine pranobex in airway inflammation, airway morbidity, not applicable and 1 more, sponsored by Gedeon Richter Plc. Primary endpoint: Short-term efficacy of Groprinosin. Started Jan 2014; status: terminated.
02
Drugs
inosine pranobex
03
Conditions
airway inflammationairway morbiditynot applicableallergy
Beyond the preview
Go deeper on 2013-003303-18.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-003303-18.